Fludara
information and resources from the National Cancer Institute
fludarabine
Palliative treatment of patients with B-cell lymphocytic leukemia (CLL) who have not responded or have progressed during treatment with at least one standard alkylating agent containing regimen.
Berlex Laboratories Inc. Apr 18 1991
|
|
|
|
news articles
Cell Genesys to Present Data From GVAX(R) Cancer Immunotherapy and ... Mar 30, 2006
PR Newswire (press release), 5:00 pm EDT) (Abstract ID: 1398) -- An armed oncolytic vector (OV1203) expressing E. coli purine nucleoside phosphorylase (PNP) combined with Fludara(TM) shows ...
Nipent®/Cytoxan®/Rituxan® Shows High Activity in High-Risk ... Nov 23, 2005
Cancer Consultants (press release), November. One of the most active drug combinations for the treatment of CLL is Fludara® (fludarabine), Cytoxan and Rituxan. The ...
Favrille Announces Appointment of David Guy as Chief Commercial ... Dec 5, 2005
PharmaLive.com (press release), 10 years of experience specifically dedicated to commercializing oncology products and managing leading brands such as Rituxan, Herceptin(R), Fludara(R) and ...
Treatment with Subcutaneous (SC) MabCampath(R) (alemtuzumab) is ... Dec 12, 2005
PR Newswire UK (press release), ...antibody approved for CLL and the first drug with proven efficacy in CLL patients who have failed both alkylating agents and Fludara (fludarabine phosphate ...
Favrille Announces Appointment of David Guy as Chief Commercial ... Dec 5, 2005
Yahoo! News (press release) ...years of experience specifically dedicated to commercializing oncology products and managing leading brands such as Rituxan, Herceptin®, Fludara® and Taxotere ...
|
|
